Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 2
2004 3
2005 2
2006 7
2007 3
2008 3
2009 2
2011 3
2012 2
2013 4
2014 9
2015 7
2016 10
2017 8
2018 9
2019 10
2020 7
2021 13
2022 24
2023 40
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Among authors: zaki m. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M. Miguel JS, et al. Among authors: zaki m. Lancet Oncol. 2013 Oct;14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2. Epub 2013 Sep 3. Lancet Oncol. 2013. PMID: 24007748 Clinical Trial.
miRNAs driving diagnosis, prognosis and progression in Merkel cell carcinoma.
Al-Noshokaty TM, Elballal MS, Helal GK, Abulsoud AI, Elshaer SS, El-Husseiny AA, Fathi D, Abdelmaksoud NM, Abdel Mageed SS, Midan HM, Zaki MB, Abd-Elmawla MA, Rizk NI, Elrebehy MA, Zewail MB, Mohammed OA, Doghish AS. Al-Noshokaty TM, et al. Among authors: zaki mb. Pathol Res Pract. 2023 Sep;249:154763. doi: 10.1016/j.prp.2023.154763. Epub 2023 Aug 14. Pathol Res Pract. 2023. PMID: 37595447 Review.
Possible role of miRNAs in pheochromocytoma pathology - Signaling pathways interaction.
Elkhawaga SY, Elshafei A, Elkady MA, Yehia AM, Abulsoud AI, Abdelmaksoud NM, Elsakka EGE, Ismail A, Mokhtar MM, El-Mahdy HA, Hegazy M, Elballal MS, Mohammed OA, Abdel-Reheim MA, El-Dakroury WA, Abdel Mageed SS, Elrebehy MA, Shahin RK, Zaki MB, Doghish AS. Elkhawaga SY, et al. Among authors: zaki mb. Pathol Res Pract. 2023 Nov;251:154856. doi: 10.1016/j.prp.2023.154856. Epub 2023 Oct 5. Pathol Res Pract. 2023. PMID: 37806171 Review.
Antitrypanosomal activity of new semi-synthetic bergenin derivatives.
El-Hawary SS, Mohammed R, AbouZid S, Zaki MA, Ali ZY, Elwekeel A, Elshemy HAH. El-Hawary SS, et al. Among authors: zaki ma. Chem Biol Drug Des. 2022 Feb;99(2):179-186. doi: 10.1111/cbdd.14000. Epub 2021 Dec 29. Chem Biol Drug Des. 2022. PMID: 34967118
The emerging role of miRNAs in Merkel cell carcinoma pathogenesis: Signaling pathway crosstalk.
Rizk NI, Midan HM, Helal GK, Abulsoud AI, Elshaer SS, El-Husseiny AA, Fathi D, Abdelmaksoud NM, Abdel Mageed SS, Elballal MS, Zaki MB, Abd-Elmawla MA, Al-Noshokaty TM, Elrebehy MA, El-Dakroury WA, Abulsoud LA, Doghish AS. Rizk NI, et al. Among authors: zaki mb. Pathol Res Pract. 2023 Sep;249:154771. doi: 10.1016/j.prp.2023.154771. Epub 2023 Aug 19. Pathol Res Pract. 2023. PMID: 37611429 Review.
161 results